{
    "organizations": [],
    "uuid": "948e9a2416f4a8756ccf05e2641588324bd21b7f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sancilio-pharma-says-sickle-cell-t/brief-sancilio-pharma-says-sickle-cell-treatment-receives-ema-orphan-drug-status-idUSFWN1RG0FT",
    "ord_in_thread": 0,
    "title": "BRIEF-Sancilio Pharma Says Sickle Cell Treatment Receives EMA Orphan Drug Status",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - Sancilio Pharmaceuticals Co Inc :\n* COMPANY ANNOUNCES ALTEMIA™ RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE (SCD)\n* ‍SPCI PLANS TO PRESENT DETAILED DATA FROM COMPLETED SCOT PHASE 2 STUDY IN PEER REVIEWED JOURNALS & SCIENTIFIC CONFERENCES​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T20:16:00.000+03:00",
    "crawled": "2018-04-04T12:13:04.037+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "sancilio",
        "pharmaceutical",
        "co",
        "inc",
        "company",
        "announces",
        "receives",
        "orphan",
        "drug",
        "designation",
        "european",
        "medicine",
        "agency",
        "treatment",
        "pediatric",
        "patient",
        "sickle",
        "cell",
        "disease",
        "scd",
        "plan",
        "present",
        "detailed",
        "data",
        "completed",
        "scot",
        "phase",
        "study",
        "peer",
        "reviewed",
        "journal",
        "scientific",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}